This CME program is derived from content presented at the Congress of Clinical Rheumatology West 2025 Meeting. The expert faculty, Dr. Joan Merrill, will first review the pathophysiology and mode of action of CAR T-cell therapy for patients with severe refractory systemic lupus erythematosus (SLE). Following, Dr. Merrill will analyze current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus, as well as clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE. To conclude, Dr. Merrill will discuss how to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE.
Rheumatologists and other healthcare professionals who manage patients with SLE
Review the pathophysiology and mode of action of CAR T-cell therapy
Review the current clinical options, unmet needs, and emerging therapies for patients with severe, refractory systemic lupus erythematosus
Analyze the clinical trial data and clinical applications of CAR T-cell therapy to treat patients with severe, refractory SLE
Develop strategies to incorporate patient shared decision making when discussing CAR T-cell therapy for SLE
Review Clinical Options for the Management of Patients with Severe, Refractory SLE
Pathophysiology and Mode of Action of CAR T-cell Therapies for Autoimmune Disorders
Analyze the Current Clinical Trial Data for CAR T-cell Therapies to Treat Patients with Severe, Refractory SLE
Review Applications and Logistics of CAR T-cell Treatments and Patient Education
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Joan T. Merrill, MD | Consultant/Advisor: AbbVie Inc.; Amgen Inc.; AstraZeneca; Biogen; Boehringer Ingelheim; Bristol Myers Squibb; EMD Serono; Genetech/Roche; GSK; Janssen; Lilly; Merck MSD; RemeGen Biosciences; Sanofi; UCB; Zenas BioPharma, Inc. Speaker: AbbVie Inc.; Biogen; Bristol Myers Squibb; EMD Serono; GSK; Merck MSD; Sanofi; Zenas BioPharma, Inc. IST: Bristol Myers Squibb; GSK |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditTM.
AcademicCME designates this enduring material for a maximum of 1.25 CNE Contact Hour.
AcademicCME designates this continuing education activity for 1.25 CPE Contact Hours (.125 CEUs) of continuing pharmacy education credit (UAN JA4008190-0000-25-031-H01-P).
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Bristol Myers Squibb
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com
